|
Porker of the Month: Sen. Cory Booker
President’s SOTU Is an Alternate Universe
CAGW
responded to President Obama’s January 20 State of the Union (SOTU)
address by noting that it would have made a good episode of “The
Twilight Zone.” In “The Obama Zone,” there is no national debt, because
the President never mentioned it during his entire speech. There is no
government waste, fraud, abuse, or mismanagement, which also went
unmentioned, as did duplicative or overlapping federal programs.
Seemingly, every federal program is in perfect working order. President
Obama failed to acknowledge that taxpayers would be footing the bill
for his “free” community college plan, just as property taxes pay for
the “free” high school he cited. The President also never made reference
to the worsening financial woes of Social Security and Medicare, the
two largest and most popular government entitlement programs. CAGW
concluded that the speech was a waste of taxpayers’ time and money. Read more of CAGW’s reaction to the SOTU.
From “The Swine Line” …
This month, the Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee recommended approval of the first biosimilar drug,
called filgrastim, reports CAGW Health and Science Director Elizabeth
Wright on CAGW’s “Swine Line” blog. One of the few good things to come
out of the Affordable Care Act, better known as ObamaCare, the Biologics
Price Competition and Innovation Act created an abbreviated pathway for
bringing the “generic” versions of biologic drugs,
more properly called biosimilars, to the marketplace. Biologics are
made from living organisms, as opposed to chemically-based drugs, and
offer a promising, vital new therapy for millions of Americans.
However, the high cost of these drugs has stirred concern and
controversy. Biosimilars provide a safe and effective alternative to
brand-name biologics once their patents have expired, and a November,
2014 Rand Corporation study found that introducing competing biosimilars, currently sold in more than 40 countries,
into the U.S. marketplace could cut spending on biologics in the U.S.
by $44 billion over the next decade. Wright concludes by noting that
the FDA advisory panel’s decision was both exciting and historic, but
the introduction of filgrastim into the U.S. still faces barriers that
the FDA must resolve before granting official approval, hopefully by
March, which would give patients access to the drug by the end of the
year. Read more about cost-saving biosimilar drugs.
|
Thursday, January 29, 2015
CITIZENS AGAINST GOVERNMENT WASTE 01/29/2015
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment